Feature ArticlesIdentification and Management of Prescription Drug Abuse in PregnancyWorley, Julie PhDAuthor Information Rush University College of Nursing, Chicago, Illinois. Corresponding Author: Julie Worley, PhD, Rush University College of Nursing, 600 S. Paulina, Chicago, IL 60612 (email@example.com). Disclosure: The author has disclosed that she has no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Submitted for publication: January 6, 2014; accepted for publication: April 3, 2014. The Journal of Perinatal & Neonatal Nursing: July/September 2014 - Volume 28 - Issue 3 - p 196–203 doi: 10.1097/JPN.0000000000000039 Buy Metrics Abstract Prescription drug abuse is a growing problem in the United States and many other countries. Estimates of prescription drug abuse rates during pregnancy range from 5% to 20%. The primary prescription drugs designated as controlled drugs with abuse potential in pregnancy are opiates prescribed for pain, benzodiazepines prescribed for anxiety, and stimulants prescribed for attention-deficit/hyperactivity disorder. Prescription drugs are obtained for abuse through diversion methods, such as purchasing them from others or by doctor shopping. The use of prescription drugs puts both the mother and the fetus at high risk during pregnancy. Identification of women who are abusing prescription drugs is important so that treatment can be ensured. It is crucial for healthcare professionals to use a multidisciplinary approach and be supportive and maintain a good rapport with pregnant women who abuse prescription drugs. Management includes inpatient hospitalization for detoxification and withdrawal symptoms, and in the case of opiate abuse, opiate maintenance is recommended for pregnant women for the duration of their pregnancy to reduce relapse rates and improve maternal and fetal outcomes. Other recommendations include referral for support groups and supportive housing. © 2014 by Wolters Kluwer Health | Lippincott Williams & Wilkins.